Biogen Proposes $442 Million Acquisition of Sage Therapeutics at $7.22 Per Share, Shares Surge 37%

Biogen Proposes $442 Million Acquisition of Sage Therapeutics at $7.22 Per Share, Offering 30% Premium as Stock Jumps 35%

Biogen CEO Confirms Intent to Acquire Biotechs, Including $469 Million Offer for Sage Therapeutics

Biogen Offers $469 Million for Sage Therapeutics, Developer of Zurzuvae for Postpartum Depression

Biogen Offers to Acquire Sage Therapeutics for $7.22 Per Share, 30% Premium; Stock Rises 34% After FDA-Approved Zurzuvae